Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype

OBJECTIVE: To evaluate mepolizumab's efficacy in eosinophilic granulomatosis with polyangiitis (EGPA) with and without a vasculitic phenotype. METHODS: The MIRRA study (NCT02020889/GSK ID: 115921) included adults with relapsing/refractory EGPA and 4 or more weeks of stable oral glucocorticoids...

Descripción completa

Detalles Bibliográficos
Autores principales: Terrier, Benjamin, Jayne, David R.W., Hellmich, Bernhard, Bentley, Jane H., Steinfeld, Jonathan, Yancey, Steven W., Kwon, Namhee, Akuthota, Praveen, Khoury, Paneez, Baylis, Lee, Wechsler, Michael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349249/
https://www.ncbi.nlm.nih.gov/pubmed/37312233
http://dx.doi.org/10.1002/acr2.11571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349249/
https://www.ncbi.nlm.nih.gov/pubmed/37312233
http://dx.doi.org/10.1002/acr2.11571

Ejemplares similares